Lb Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
LB Pharmaceuticals Inc. reports significant progress in its clinical pipeline, with lead candidate LB-102 entering Phase 3 for acute schizophrenia and Phase 2 for bipolar depression, alongside a recent $100 million capital raise.